Liver Cancer/HCC
Liver Cancer/HCC
EASL 2013: Long-term Tenofovir Reduces Liver Cancer Risk in People with Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Friday, 26 April 2013 00:00
- Written by Liz Highleyman
Long-term treatment with tenofovir (Viread) lowered the risk of developing hepatocellular carcinoma among people with chronic hepatitis B, with a notable divergence from expected rates after about 5 years, according to a report presented at the at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
Heavy Alcohol Use Increases Liver Cancer Risk for People with Hepatitis B
- Details
- Category: HBV Disease Progression
- Published on Thursday, 24 January 2013 00:00
- Written by Liz Highleyman
Hepatitis B patients with liver cirrhosis who consumed large amounts of alcohol were more likely to develop hepatocellular carcinoma (HCC) than people who drank less, according to a report in the December 6, 2012, online edition of the Journal of Hepatology. However, antiviral treatment can help prevent liver cancer.
AASLD 2012: Patients with Cirrhosis Can Respond Well to Boceprevir or Telaprevir with Careful Monitoring
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 04 December 2012 00:00
- Written by Liz Highleyman
Real-world experience in the French early-access CUPIC study shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivek), although adverse events are common, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
Liver Disease Is Leading Cause of Death for People with Chronic Hepatitis B
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 15 January 2013 00:00
- Written by Liz Highleyman
Advanced liver disease caused by hepatitis B virus (HBV) -- including hepatocellular carcinoma (HCC) and decompensated cirrhosis -- accounted for more than 40% of deaths of people with chronic hepatitis B in a large health maintenance organization, researchers reported in the December 12, 2012, advance online edition of Hepatology.
AASLD 2012: Brivanib Fails to Match Sorafenib for Liver Cancer, but Tivatinib Looks Promising
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 30 November 2012 00:00
- Written by Liz Highleyman
The investigational cancer drug brivanib did not significantly increase overall survival for patients with hepatocellular carcinoma compared with existing standard therapy, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this month in Boston. But another drug, tivatinib, did appear beneficial for a subset of patients.
More Articles...
- AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?
- AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern
- Researchers Shed Light on how Hepatitis B Virus Causes Liver Cancer
- EASL 2012: Brivanib Did Not Improve Overall Liver Cancer Survival, but Did Show Anti-tumor Activity
Web Design and Development by